Frequency and severity of headache is worsened by interferon-β therapy in patients with multiple sclerosis

Acta Neurologica Scandinavica

Volumn 125, Issue 2, 2012, Pages 91-95

  Patti, F ^a   Nicoletti, A ^a   Pappalardo, A ^a   Castiglione, A ^a   Lo Fermo, S ^a   Messina, S ^a   D'Amico, E ^a   Cimino, V ^a   Zappia, M ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Adverse effects; Demyelinating diseases; Migraine; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDUCED HEADACHE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTIPLE SCLEROSIS; PAIN ASSESSMENT; QUESTIONNAIRE; RELAPSE; RISK ASSESSMENT; TREATMENT RESPONSE;

ADULT; FEMALE; HEADACHE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TENSION-TYPE HEADACHE;

EID: 84855940102     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01532.x     Document Type: Article

References (33)

1. Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol 1984;41:1270-2.
2. D'Amico D, La Mantia L, Rigamonti A et al. Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia 2004;24:980-4.
3. Freedman MS, Gray TA. Vascular headache: a presenting symptom of multiple sclerosis. Can J Neurol Sci 1989;16:63-6.
4. Poser CM, Presthus J, Horsda O. Clinical characteristics of autopsy-proved multiple sclerosis. Neurology 1966;16:791-8.
5. Watkins MS, Espir M. Migraine and multiple sclerosis. J Neurol Neurosurg Psychiatry 1969;32:35-7.
6. Rio J, Nos C, Bonaventura I et al. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology 2004;63:525-8.
7. La Mantia L, D'Amico D, Rigamonti A et al. Interferon treatment may trigger primary headaches in multiple sclerosis patients. Mult Scler 2006;12:476-80.
8. Brandes JL. Migraine induced by interferon beta therapy for multiple sclerosis. Neurology 2000;54(Suppl. 3):A422.
9. Pöllmann W, Erasmus LP, Feneberg W, Then Bergh F, Straube A. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology 2002;59:636-9.
10. Tremlett HL, Oger J. Interrupted therapy. Stopping and switching of the ß-interferons prescribed for MS. Neurology 2003;61:551-4.
11. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
12. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
13. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinincal Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
15. Olesen J, Steiner TJ. The International classification of headache disorders. 2nd edn (ICDH-II). J Neurol Neurosurg Psychiatry 2004;75:808-11.
16. Beghi E, Monticelli ML, Amoruso L, Zarrelli MM, Italian General Practitiones Study Group. Prevalence, characteristics and patterns of health care use for chronic headache in two areas of Italy. Results of a questionnaire interview in general practice. Cephalalgia 2003;23:175-82.
17. Nicoletti A, Patti F, Lo Fermo S et al. Headache and multiple sclerosis: a population-based case-control study in Catania, Sicily. Cephalalgia 2008;25:1163-9.
18. Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Olesen J. Classification of primary headaches. Neurology 2004;63:427-35.
19. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing-remitting multiple sclerosis. Ann Neurol 1996;39:285-94.
20. The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicentric, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
21. The PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-504.
22. Kumpfel T, Then Bergh F, Pollmacher T et al. Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS. Neurology 2000;55:1231-3.
23. Munno I, Marinaro M, Bassi A et al. Immunological aspects in migraine: increase of IL-10 plasma levels during attack. Headache 2001;41:764-7.
24. Liu YW, Chen CC, Tseng HP, Chang WC. Lipopolysaccharide-induced transcriptional activation of interleukin-10 is mediated by MAPK- and NF-κB-induced CCAAT/enhancer-binding protein δ in mouse macrophages. Cell Signal 2006;18:1492-500.
25. Yang CH, Murti A, Pfeffer SR et al. IFNα/β promotes cell survival by activating NF-κB. Proc Natl Acad Sci 2000;97:13631-6.
26. Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002;51:507-16.
27. Ersoy E, Kus CNS, Sener U, Coker I, Zorlu Y. The effects of interferon-b on interleukin-10 in multiple sclerosis patients. Eur J Neurol 2005;12:208-11.
28. Huang YM, Adikari S, Bave U, Sanna A, Alm G. Multiple sclerosis: interferon-beta induces CD123(+)BDCA2-dendritic cells that produce IL-6 and IL-10 and have no enhanced type I interferon production. J Neuroimmunol 2005;158:204-12.
29. Rothuizen LE, Buclin T, Spertini F et al. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 1999;99:131-41.
30. Alam J, McAllister A, Scaramucci J. Pharmacokinetics and pharmacodynamics of interferon beta-1a in healthy volunteers after intravenous, subcutaneous or intramuscular administration. Clin Drug Invest 1997;14:35-43.
31. Wiesemann E, Sonmez D, Heidenreich F, Windhagen A. Interferon-beta increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, Il-5 and IL-10 in autologous T-cells. J Neuroimmunol 2002;123:160-9.
32. Ozenci V, Kouwenhoven M, Huang YM et al. Multiple Sclerosis: levels of interleukin-10 secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment. Scand J Immunol 1999;49:554-61.
33. Sega S, Wraber B, Msec A et al. IFN-β1a and IFN-β1b have different patterns of influence on cytokines. Clin Neurol Neurosurg 2004;106:255-8.